Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Trial watch toll-like receptor agonists for cancer therapy
Erika Vacchelli
,
Alexander Eggermont
, Catherine Sautès-Fridman
, Jérôme Galon
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Research output
:
Contribution to journal
›
Article
›
peer-review
153
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trial watch toll-like receptor agonists for cancer therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Therapy
100%
Toll-like
100%
Receptor Agonist
100%
In Cancer
28%
Cancer Patients
28%
Clinical Trials
14%
Therapeutic Potential
14%
Biological Characteristics
14%
Toll-like Receptor 4 (TLR4)
14%
Innate Immune Response
14%
Lipopolysaccharide
14%
Late Development
14%
Clinical Investigation
14%
Bacillus Calmette
14%
Imiquimod
14%
Phosphoinositide Lipid
14%
Toll-like Receptor 2 (TLR2)
14%
TLR4 Agonist
14%
Pattern Recognition Receptors
14%
Oncoimmunology
14%
Anticancer Immune Response
14%
Microbial Component
14%
Double-stranded RNA
14%
Attenuated Strain
14%
Toll-like Receptor 7 (TLR7)
14%
Safety Potential
14%
Preclinical Investigation
14%
Imidazoquinoline
14%
Mycobacterium
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Toll Like Receptor Agonist
100%
Toll Like Receptor 4
40%
Toll Like Receptor
40%
Clinical Trial
20%
Clinical Study
20%
Preclinical Study
20%
Lipopolysaccharide
20%
Imiquimod
20%
Phosphoryl Lipid A
20%
Double Stranded RNA
20%
Toll Like Receptor 2
20%
Pattern Recognition Receptor
20%
Toll Like Receptor 7
20%
Mycobacteria
20%
Immunology and Microbiology
Agonist
100%
Toll-Like Receptor
100%
TLR4
28%
Preclinical Study
14%
Immune Response
14%
Innate Immune System
14%
Phosphoryl Lipid A
14%
Imiquimod
14%
TLR2
14%
Mycobacteria
14%
Pattern Recognition Receptor
14%
TLR7
14%